Roivant Sciences Ltd.
ROIV
45 insider filings · Latest: Jul 27, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Jun 26 8:10 PM | MAYUKH SUKHATME | Proposed Sale | 500,000 | $34.08 | $17.0M | — | View → |
| Jun 25, 2026 | Jun 25 8:33 PM | MAYUKH SUKHATME | Proposed Sale | 500,000 | $34.13 | $17.1M | — | View → |
| Jun 24, 2026 | Jun 24 8:01 PM | Venker Eric | Proposed Sale | 200,000 | $33.16 | $6.6M | — | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $30.27 | $6.1M | 1,613,063(D) | View → |
| May 22, 2026 | May 22 8:00 PM | Venker Eric | Proposed Sale | 200,000 | $30.27 | $6.1M | — | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $29.59 | $5.9M | 1,647,546(D) | View → |
| Apr 16, 2026 | Apr 20 10:27 PM | Matthew GlineDirector, CEO | Sale | 289,774 | $29.16 | $8.4M | 16,736,116(D) | View → |
| Apr 20, 2026 | Apr 20 8:17 PM | Venker Eric | Proposed Sale | 200,000 | $29.59 | $5.9M | — | View → |
| Apr 16, 2026 | Apr 16 9:24 PM | Gline Matthew | Proposed Sale | 289,774 | $29.16 | $8.4M | — | View → |
| Apr 16, 2026 | Apr 16 8:33 PM | Gline Matthew | Proposed Sale | 289,774 | $29.16 | $8.4M | — | View → |
| Apr 8, 2026 | Apr 10 10:00 PM | Jennifer HumesChief Accounting Officer | Sale | 13,538 | $28.37 | $384.1K | 84,191(D) | View → |
| Apr 8, 2026 | Apr 8 8:07 PM | JENNIFER HUMES | Proposed Sale | 13,538 | $28.37 | $384.0K | — | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Sale | 70,000 | $27.45 | $1.9M | 42,963(D) | View → |
| Mar 26, 2026 | Mar 26 8:14 PM | MEGHAN FITZGERALD | Proposed Sale | 70,000 | $27.45 | $1.9M | — | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $28.24 | $5.6M | 1,647,546(D) | View → |
| Mar 16, 2026 | Mar 18 10:23 PM | Melissa B, EpperlyDirector | Sale | 41,861 | $28.68 | $1.2M | 15,804(D) | View → |
| Mar 17, 2026 | Mar 17 8:17 PM | Venker Eric | Proposed Sale | 200,000 | $28.24 | $5.6M | — | View → |
| Mar 16, 2026 | Mar 16 8:04 PM | MELISSA B EPPERLY | Proposed Sale | 41,861 | $28.68 | $1.2M | — | View → |
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Sale | 587,390 | $27.51 | $16.2M | 13,736,547(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Sale | 1,012,610 | $27.15 | $27.5M | 13,736,547(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Jul 30 1:00 AM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,044,834(D) | View → |
| Jun 30, 2026 | Jul 2 11:03 PM | Meghan FitzgeraldDirector | Option Exercise | 10,000 | $8.80 | 38,578(D) | View → |
| Jun 29, 2026 | Jul 1 10:34 PM | Melissa B, EpperlyDirector | Option Exercise | 17,750 | $4.46 | 169,166(D) | View → |
| Jun 26, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,224,363(D) | View → |
| Jun 25, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,724,363(D) | View → |
| Jun 24, 2026 | Jun 26 10:13 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,244,834(D) | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,444,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,644,834(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Richard PulikCFO | Grant/Award | 84,026 | $29.08 | 84,026(D) | View → |
| Apr 20, 2026 | Apr 22 10:26 PM | Jennifer HumesChief Accounting Officer | Grant/Award | 27,157 | $29.08 | 27,157(D) | View → |
| Mar 30, 2026 | Apr 1 11:20 PM | Matthew GlineDirector, CEO | Option Exercise | 2,178,150 | — | 0(D) | View → |
| Mar 30, 2026 | Apr 1 11:19 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 1,306,889 | — | 0(D) | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Option Exercise | 70,000 | $8.80 | 48,578(D) | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,844,834(D) | View → |
| Feb 23, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 587,390 | $3.85 | 3,026,184(D) | View → |
| Feb 20, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,012,610 | $3.85 | 3,613,574(D) | View → |
| Feb 19, 2026 | Feb 24 1:40 AM | Frank TortiPresident and Vant Chair | Option Exercise | 1,400,000 | $3.85 | 4,626,184(D) | View → |
| Feb 13, 2026 | Feb 18 10:57 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 5,044,834(D) | View → |
| Feb 9, 2026 | Feb 11 10:53 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 651,558 | $12.68 | 0(D) | View → |